Immuron Ltd - Asset Resilience Ratio
Immuron Ltd (IMC) has an Asset Resilience Ratio of 29.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Immuron Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Immuron Ltd's Asset Resilience Ratio has changed over time. See IMC book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Immuron Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Immuron Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.04 Million | 29.97% |
| Total Liquid Assets | AU$3.04 Million | 29.97% |
Asset Resilience Insights
- Very High Liquidity: Immuron Ltd maintains exceptional liquid asset reserves at 29.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immuron Ltd Industry Peers by Asset Resilience Ratio
Compare Immuron Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Immuron Ltd (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Immuron Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 29.97% | AU$3.04 Million ≈ $2.15 Million |
AU$10.13 Million ≈ $7.17 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.55 Million ≈ $11.00 Million |
-- |
| 2023-06-30 | 8.34% | AU$1.83 Million ≈ $1.30 Million |
AU$21.99 Million ≈ $15.56 Million |
+0.96pp |
| 2022-06-30 | 7.38% | AU$1.83 Million ≈ $1.30 Million |
AU$24.86 Million ≈ $17.59 Million |
-43.77pp |
| 2018-06-30 | 51.15% | AU$4.73 Million ≈ $3.34 Million |
AU$9.24 Million ≈ $6.54 Million |
+2.94pp |
| 2017-06-30 | 48.21% | AU$3.99 Million ≈ $2.83 Million |
AU$8.29 Million ≈ $5.86 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$8.83 Million ≈ $6.25 Million |
-- |
| 2006-06-30 | 16.60% | AU$1.10 Million ≈ $778.32K |
AU$6.63 Million ≈ $4.69 Million |
-26.59pp |
| 2005-06-30 | 43.19% | AU$3.48 Million ≈ $2.46 Million |
AU$8.05 Million ≈ $5.70 Million |
+22.83pp |
| 2004-06-30 | 20.37% | AU$1.00 Million ≈ $707.56K |
AU$4.91 Million ≈ $3.47 Million |
-15.40pp |
| 2003-06-30 | 35.77% | AU$2.13 Million ≈ $1.51 Million |
AU$5.96 Million ≈ $4.21 Million |
-6.81pp |
| 2002-06-30 | 42.57% | AU$2.80 Million ≈ $1.98 Million |
AU$6.58 Million ≈ $4.65 Million |
-15.35pp |
| 2001-06-30 | 57.92% | AU$4.54 Million ≈ $3.21 Million |
AU$7.83 Million ≈ $5.54 Million |
-30.91pp |
| 2000-06-30 | 88.83% | AU$4.00 Million ≈ $2.83 Million |
AU$4.50 Million ≈ $3.19 Million |
-- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more